Tag collegati:
Macuira | 5 | Revolución Molecular Disipada
Episode 143 | What You Eat Matters, The Doctor with a Holistic Approach | Guest: Dr. Emi Hosoda
E12. ¿Qué hacer si doy positivo a COVID-19?
O fracasso da política de testagem de Covid no Brasil
Il Molecular Tumor Board, uno strumento chiave al servizio dell’oncologia di precisione
I'll do it whn you blessing. mixdown
Aplicaciones de la biología molecular en la biotecnología
Tecnología de punta al alcance de la comunidad yumurina
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
What is MyCancerGenome.org?
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing
Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
Dr. WIlliam Pao on the Goals for Developing MyCancerGenome.org
Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials
Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
Scopri di più
Cerca
